Novolog (NVLG) AI Stock Analysis

• Market Cap: ₪363.74M
• Dividend Yield: 5.5%
• Average Volume (3M): 482.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: -13.76%
• EPS Growth: -103.31%
• Country: IL
• Employees: 916
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Distribution
• EPS (TTM): N/A
• Shares Outstanding: 510,874,760
• 10 Day Avg. Volume: 208,337
• 30 Day Avg. Volume: 482,268
• PEG Ratio: -1.73
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 0.36
• P/FCF Ratio: -18.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: 84.00 ▲(9.80% Upside)
• Action: Reiterated
• Date: 08/25/26

Positive Factors

Strong TTM Revenue Growth

The sharp TTM revenue increase indicates stronger distribution activity and market demand. If sustained, expanding scale can improve operating leverage and strengthen Novolog’s competitive position, although profitability must catch up.

Negative Factors

Negative TTM Earnings

The move to a TTM net loss shows that revenue growth is not currently translating into reliable shareholder earnings. Persistent losses could restrict reinvestment, weaken financial flexibility and make the business more vulnerable to operating setbacks.

Novolog Business Overview & Revenue Model

Company Description

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and med...

Read more

Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and med...

Novolog Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.81B	1.81B	2.02B	1.64B	1.51B	1.26B
Gross Profit	137.75M	124.09M	180.78M	173.76M	176.15M	148.96M
EBITDA	105.05M	100.75M	149.39M	130.14M	138.53M	115.92M
Net Income	-674.00K	4.12M	39.54M	-42.00M	47.51M	42.32M
Balance Sheet
Total Assets	2.71B	2.15B	3.04B	2.79B	2.43B	2.29B
Cash, Cash Equivalents and Short-Term Investments	204.46M	121.77M	247.60M	232.94M	172.81M	238.71M
Total Debt	171.19M	183.20M	198.47M	215.18M	212.77M	166.81M
Total Liabilities	2.35B	1.78B	2.65B	2.39B	1.97B	1.86B
Stockholders Equity	350.91M	356.85M	368.38M	371.08M	436.00M	424.37M
Cash Flow
Free Cash Flow	71.82M	-34.22M	99.78M	129.06M	63.16M	52.75M
Operating Cash Flow	70.18M	-16.50M	158.52M	200.01M	132.65M	83.39M
Investing Cash Flow	-40.34M	-61.92M	-50.55M	-72.60M	-124.95M	-69.07M
Financing Cash Flow	-48.86M	-46.02M	-94.59M	-67.71M	-72.96M	47.49M

Novolog Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 76.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 76.5 is above the 20-day moving average (MA) of 76.28, above the 50-day MA of 75.05, and below the 200-day MA of 100.70, indicating a bearish trend. The MACD of -1.05 indicates Positive momentum. The RSI at 36.25 is Neutral, neither overbought nor oversold. The STOCH value of 6.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.

Novolog Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVLG	60 Neutral	₪363.74M	-547.69	―	5.50%	-13.76%	-103.31%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%